30 results about "Nucleic acid structure" patented technology

The present application relates to the technical field of nucleic acid detection, in particular to a RNA pathogen chemiluminescence detection method based on nucleic acid structure and sequence characteristics. The present application provides a pathogen RNA rapid detection technology based on the reporter molecule cyclization combined with rolling circle amplification according to the secondary structure and sequence characteristics of RNA, which is suitable for high-sensitivity and high-specificity detection of RNA pathogens such as respiratory viruses. The present application innovatively combines the target structure characteristics with sequence specificity, breaks through the traditional sequence-dependent isothermal amplification technology, realizes the highly specific reporter molecule cyclization, significantly improves the detection reliability, and does not require complex instruments. After the swab sample is collected, the pathogen RNA is rapidly released by using a nucleic acid releasing agent, without complex purification steps, and the reading can be realized through a common chemiluminescence instrument, which is suitable for primary site detection.

The invention discloses a cell membrane in-situ drug membrane protein target screening method based on variable configuration DNA, and belongs to the technical field of biological medicine. Two pairs of functionalized nucleic acid structures are constructed, the first pair is S1S2 semi-complementary DNA double strands, the second pair is S3S4 DNA-RNA hybrid double strands, and the S1S2 structure is covalently coupled to a non-natural amino acid site-directed modified membrane protein through a click chemical reaction in a living cell to realize tagging of the membrane protein; when the candidate drug coupled in S3 interacts with the membrane protein, triggering an allosteric response system to release the tagged chain in S1; the released DNA tag is subjected to PCR amplification and sequencing, and accurate identification and analysis of a membrane protein target are realized according to a tag sequence. The invention provides a high-specificity and non-in-vitro drug membrane protein target screening technology. According to the technology, active compound discovery or accurate screening of drug membrane protein targets in a living cell in-situ environment can be realized.

The invention relates to the technical field of nucleic acid detection, in particular to an RNA pathogen chemiluminescence detection method based on a nucleic acid structure and sequence characteristics. The invention provides a pathogen RNA rapid detection technology which is based on RNA secondary structure and sequence characteristic reporter molecule cyclization and is combined with rolling circle amplification, and is suitable for high-sensitivity and high-specificity detection of RNA pathogens such as respiratory viruses. Target structure characteristics and sequence specificity are creatively combined, a traditional sequence-dependent isothermal amplification technology is broken through, high-specificity reporter molecule cyclization is achieved, the detection reliability is remarkably improved, complex instruments are not needed, after swab samples are collected, pathogen RNA is rapidly released through a nucleic acid releasing agent, complex purification steps are not needed, and the method is suitable for large-scale popularization and application. And reading can be realized through a common chemiluminiscence instrument, and the method is suitable for base-level field detection.

The application discloses a method for constructing a high-throughput protein capture interface by antibody adsorption, which comprises the following steps: S1, synthesizing a tetrahedral framework nucleic acid structure; S2, mixing a capture antibody and the synthesized tetrahedral framework nucleic acid structure on a gold island substrate to prepare a high-throughput protein capture interface; S3, placing the gold island substrate in a wet box for overnight incubation; S4, blocking the capture interface to prevent non-specific adsorption; S5, incubating a protein target; S6, incubating a detection antibody; S7, incubating a fluorescent secondary antibody; S8, washing the capture interface with pure water and centrifuging and air-drying; and S9, performing fluorescent imaging and quantification on the capture interface by using a chip scanner. The method for constructing a high-throughput protein capture interface by antibody adsorption has high uniformity, and can realize high-throughput, high-sensitivity and high-accuracy protein capture and quantitative detection.

Disclosed herein are methods and compositions for enhancing delivery and function of vaccine components, immunotherapy Agents, and improved delivery of nucleic acid nanostructures, nucleic acids, peptides, polypeptides, and other types of cargoes. These methods and compositions utilize design components suitable for rapid and cost-effective manufacturing, and are designed to exclusively use the process of self-assembly to form nanotherapeutics requiring no purification in many instances.

The present invention relates to a novel gene therapeutic agent capable of inhibiting FABP4 and / or FABP5, and relates to a nucleic acid construct capable of inhibiting target gene(s), FABP4 and / or FABP5, and use thereof for treating obesity or obesity-derived metabolic diseases. The nucleic acid construct according to the present invention effectively inhibits the expression of FABP4 and / or FABP5 by targeting adipocytes, thereby achieving the effects of reducing body weight, reducing inflammatory cytokines in adipose tissue, reducing lipids, and ameliorating insulin resistance and glucose tolerance, and thus can be used in the development of therapeutic agents for obesity or obesity-derived metabolic diseases.

The present disclosure in some aspects relates to methods and compositions for accurately detecting and quantifying multiple analytes present in a biological sample. In some aspects, the methods and compositions provided herein address one or more issues associated with the stability and / or size of nucleic acid structures such as rolling circle amplification products in the biological sample.

The present disclosure in some aspects relates to methods and compositions for accurately detecting and quantifying multiple analytes present in a biological sample. In some aspects, the methods and compositions provided herein address one or more issues associated with the stability and / or size of nucleic acid structures, such as RCPs, in the biological sample without the use of exogenously added oligonucleotide compaction probes. In some embodiments, provided herein are methods involving the use of self-hybridizing hybridizing regions for compacting and / or stabilizing nucleic acid concatemers (e.g., RCPs). In some embodiments, dynamic inter-strand annealing between tandem units of an RCP is used for compaction and / or stabilization. In some embodiments, short palindromic regions in an RCP are used for compaction and / or stabilization.

This invention provides constructs and methods for modulating the relative expression of transgenes. [Solution] In a first aspect, the present invention provides a nucleic acid construct comprising a first-objective nucleotide sequence (NOI1); a flame slip motif or translational read-through motif (FSM / TRM); and a second-objective nucleotide sequence (NOI2). The nucleic acid construct may also include nucleotide sequences encoding cleavage sites (CLs) such that NOI1 and NOI2 are expressed as distinct proteins.

The present disclosure in some aspects relates to methods and compositions for accurately detecting and quantifying multiple analytes present in a biological sample. In some aspects, the methods and compositions provided herein address one or more issues associated with the stability and / or size of nucleic acid structures, such as RCPs, in the biological sample without the use of exogenously added oligonucleotide compaction probes. In some embodiments, provided herein are methods involving the use of self-hybridizing hybridizing regions for compacting and / or stabilizing nucleic acid concatemers (e.g., RCPs). In some embodiments, dynamic inter-strand annealing between tandem units of an RCP is used for compaction and / or stabilization. In some embodiments, short palindromic regions in an RCP are used for compaction and / or stabilization.

The application discloses a tetrahedral framework nucleic acid complex loaded with equol and application of the complex in preparation of a medicine for relieving fatty liver disease. The complex is obtained by stable combination of tetrahedral framework nucleic acid and equol through hydrogen bond and hydrophobic interaction; the equol is loaded on the tetrahedral framework nucleic acid structure, and can be slowly released, so that the bioavailability of the equol is improved, and the problems of poor water solubility and low stability of the equol are effectively overcome. Meanwhile, the complex can inhibit lipid accumulation in HepG2 cells, relieve lipid deposition of liver cells, and reduce accumulation of TG and T-CHO in cells, and can be used for relieving fatty liver, and preparing more and more efficient fatty liver treatment medicines, and has wide application potential in intervention of lipid metabolism disorder and related metabolic diseases.

The invention discloses a bionic black phosphorus nano material as well as preparation and application thereof. The preparation method comprises the following steps: S1, preparing black phosphorus nanosheets; s2, preparing a carboxylated black phosphorus nanosheet; s3, preparing a composite black phosphorus nano material; and S4, preparing the bionic black phosphorus nano material. The structure core of the bionic black phosphorus nanomaterial is composed of black phosphorus nanosheets, and after the black phosphorus nanosheets are modified by double-terminal carboxyl polyethylene glycol, the black phosphorus nanosheets can be covalently linked with an amino-modified Anti miR 33 nucleic acid inhibitor through terminal carboxyl of the black phosphorus nanosheets, so that the aims of protecting the nucleic acid structure and improving the delivery efficiency are fulfilled; and then coating the material by adopting a cell membrane derived from M2c phenotype macrophages, so as to endow the material with an active targeting capability in an inflammatory region.

The invention provides a game assembly system for nucleic acid structure and genetic information transfer teaching. The assembly system adopts entity cards which can be independently operated and combined, and is divided into at least five levels according to a nucleic acid structure composition relationship: a nucleic acid whole body, DNA / RNA or a nucleotide set, a nucleotide category, and specific nucleotides and basic structure units (basic groups, pentose and phosphoric acid). Each basic unit is provided with a connecting structure, each nucleotide card is provided with a receiving structure, the connecting structures and the receiving structures are differentially coded according to a composition relation, and corresponding nucleotides can be formed by stable connection only when the types and the number of the selected basic units are matched; and physical mistake proofing is realized, and the teaching intuition and accuracy are improved by displaying the hierarchical composition of nucleic acid through the corresponding inclusion of the high-level and low-level components.

The application discloses a kind of bionic black phosphorus nanomaterial and its preparation and application, including the following steps: S1, the preparation of black phosphorus nanosheet;S2, the preparation of carboxylated black phosphorus nanosheet;S3, the preparation of composite black phosphorus nanomaterial;S4, the preparation of bionic black phosphorus nanomaterial.The structural core of the bionic black phosphorus nanomaterial is composed of black phosphorus nanosheet, which can be covalently connected to the amino-modified Anti miR 33 nucleic acid inhibitor through its terminal carboxyl group after modification by double-end carboxyl polyethylene glycol, to achieve the purpose of protecting nucleic acid structure and improving delivery efficiency, and then the material is coated with cell membrane derived from M2c phenotype macrophages, thereby endowing the material with active targeting ability in inflammatory areas.

The invention belongs to the field of nanotechnology, and relates to a method for constructing condensed fluid droplets based on tetrahedral framework nucleic acid, which comprises the following steps: dissolving and diluting DNA dry powder with enzyme-free water to obtain a DNA solution, mixing four chains A, B, C and D of the obtained tetrahedral framework nucleic acid in a 50mM TM buffer solution, and carrying out polymerase chain reaction to obtain a tetrahedral framework nucleic acid structure, performing thermal insulation water bath or cooling annealing treatment on the tetrahedral framework nucleic acid structure to obtain framework nucleic acid condensation liquid drops; according to the method, a tetrahedral framework nucleic acid structure with a palindromic sequence is assembled, cohesive end sequence self-association is carried out by utilizing a salt solution, the tetrahedral framework nucleic acid is assembled into micron-sized DNA condensed liquid droplets, and a new strategy is provided for exploring a functional liquid-phase multi-stage material according to the formation and dynamic properties of the DNA condensed liquid droplets.

The invention relates to the technical field of disinfectants, in particular to a nucleic acid removal material based on a microsphere embedding technology as well as a preparation method and application of the nucleic acid removal material. The nucleic acid removing material is prepared from an oil-phase raw material and a water-phase raw material, the oil phase raw materials comprise hydrogenated lecithin, distearoyl phosphatidylcholine and cholesterol; the water-phase raw materials comprise polyethyleneimine, polyhexamethylene biguanide and benzalkonium chloride; the volume ratio of the oil-phase raw material to the water-phase raw material is 1: (2-4), the particle size of the nucleic acid removal material based on the microsphere embedding technology is 80-120nm, and the particle size distribution PDI is 0.05-0.2. According to the nucleic acid removing material based on the microsphere embedding technology, through the specific combination of the oil-phase raw material and the water-phase raw material, a nucleic acid structure can be efficiently destroyed, so that pathogens such as viruses and bacteria are thoroughly killed, and the problem that an existing disinfectant is not thorough in the aspect of killing nucleic acid is solved.

The application belongs to the technical field of protein engineering and bioluminescence analysis, and discloses a fusion protein NanoLuc-dRNH1, a preparation method and a kit thereof. The fusion protein is a single polypeptide chain, which is composed of a NanoLuc luminescent enzyme domain and a dRNH1 domain connected by a connecting peptide, and has the DNA-RNA hybrid selective binding ability and the bioluminescence signal output ability with furimazine as a substrate. The fusion protein can be recombinantly expressed in Escherichia coli and purified by affinity chromatography. Experiments show that the fusion protein forms a complex with a DNA-RNA hybrid, has low non-specific binding to single-stranded DNA, single-stranded RNA and double-stranded DNA, and generates a stable measurable luminescence signal in a short time at room temperature. Further, the kit comprising the fusion protein, furimazine and a buffer is provided, and can be used for nucleic acid structure recognition and signal reporting integrated detection, and has the advantages of simple preparation, high specificity, low background and rapid reading.

The present invention relates to a novel nucleic acid structure with improved stability and protein expression levels, and its applications, and more particularly to a nucleic acid structure comprising a coding region for encoding a polypeptide or protein; and a poly(A) tail having a secondary or tertiary structure; and a pharmaceutical composition for vaccines or gene therapy comprising the nucleic acid structure. In the case of the nucleic acid structure platform according to the present invention, improved stability and protein expression rates are observed in cells without interference with CDS, UTR sequences, etc., and therefore it can be widely and usefully used in the fields of gene therapy and vaccines.

The present invention relates to a novel nucleic acid construct with improved stability and protein expression levels and uses thereof and, more specifically, to a nucleic acid construct comprising: a coding region encoding a polypeptide or a protein; a poly(A) tail having a secondary or tertiary structure; and a non-A sequence at the 3'-terminal region, and to a pharmaceutical composition for vaccine or gene therapy comprising said nucleic acid construct. The nucleic acid construct platform according to the present invention exhibits superior stability and protein expression levels in cells without interference with CDS and UTR sequences, or other genetic elements, and thus may be broadly and advantageously used in fields such as gene therapy and vaccine applications.

The present invention relates to an HRCA method comprising the following steps: a) obtaining a nucleic acid structure formed by hybridization of at least one padlock with a target nucleic acid; b) circulating the hybridized padlock; c) subjecting the ligated circulated padlock probe to rolling circle amplification (RCA) and, if necessary, performing an MDA reaction using short primers; and d) detecting the target nucleic acid by detecting the amplified product from step c), preferably by a sequence-specific detection method.

The present invention relates to a composition for cryopreservation, comprising: a nucleic acid structure which comprises a scaffold nucleic acid folded at predetermined positions to form multiple strands, and a plurality of staple nucleic acids wherein at least a portion of a sequence thereof comprises a complementary sequence to that of the scaffold nucleic acid, which are bound to at least one of the strands of the scaffold nucleic acid to form a double strand; linkers coupled to at least one of single strands in the nucleic acid structure; and an anti-freezing peptide coupled to at least one of the linkers, so as to exhibit excellent freeze-protection effects, which in turn increase cell viability during cryopreservation of cells and tissues, while retaining original texture of food even when used for freezing the food.

The present disclosure in some aspects relates to methods and compositions for accurately detecting and quantifying multiple analytes present in a biological sample. In some aspects, the methods and compositions provided herein address one or more issues associated with the stability and / or size of nucleic acid structures such as rolling circle amplification products in the biological sample.

Products for detecting a plurality of protein analytes comprise a plurality of proximity probe pairs comprising first and second proximity probes having an antibody or antibody fragment specific for the same protein analyte and a nucleic acid domain, which probes can simultaneously bind to the analyte. Each pair is specific for a different analyte. Each nucleic acid domain comprises an ID sequence and at least a first hybridisation sequence. In each probe pair, ID sequences correspond to a particular analyte, and the probes comprise paired hybridisation sequences. For each probe pair, a splint oligonucleotide comprises hybridisation sequences complementary to each of the paired hybridisation sequences. When probes bind to their protein analyte, the respective paired hybridisation sequences can hybridise to the splint oligonucleotide. At least one pair of hybridisation sequences is shared by at least two pairs of proximity probes. A plurality of sample index oligonucleotides is also included.

The present invention relates to a novel gene therapy agent capable of inhibiting fatty acid-binding protein 5 (FABP5) and to: a nucleic acid construct that can inhibit FABP5, or FABP5 and FABP4, which are target genes; a multi-cistronic shRNA expression cassette; and uses thereof for treating obesity or obesity-induced metabolic diseases. The nucleic acid construct, or the multi-cistronic shRNA expression cassette, according to the present invention can target adipocytes, thus effectively inhibit the expression of FABP5, or FABP5 and FABP4, and thereby achieve the effects of reducing body weight, inflammatory cytokines in adipose tissues, and lipids, and improving insulin resistance and glucose resistance, and thus can be employed in the development of a therapeutic agent for obesity or obesity-induced metabolic diseases.

The application belongs to the technical field of biosensors, and particularly relates to a construction method of a light-regulated electrochemical aptamer sensor based on functionalized graphene and application thereof. The application designs and synthesizes g-C3N4-rGO heterojunction and rGO-AuNPs Schottky junction dual materials based on reduced graphene oxide (rGO), utilizes a photo-generated carrier transfer channel to regulate the rise and fall of an electroactive probe molecule methylene blue (MB) electrochemical signal, uses aptamer as a specific recognition element, uses a nucleic acid structure as a connecting bridge of the dual materials and a MB binding site, and constructs a light-regulated electrochemical aptamer sensor. The difference between an amplified background signal and a response signal is used to realize the improvement of analysis sensitivity. The application can be applied to high-sensitivity detection of mycotoxins, provides a new approach and a general method for sensitive monitoring of agricultural product fungal contamination, and has a wide application prospect.

The present invention relates to compositions of small activating nucleic acid molecules for increasing the expression of HMBS gene and a use thereof. The small activating nucleic acid molecule can be a double-stranded or single-stranded RNA molecule targeting the promoter region of the HMBS gene. The first nucleic acid strand and the second nucleic acid strand each contain a complementary region, and the complementary regions can form a double-stranded nucleic acid structure, which can promote the expression of the HMBS gene. The first nucleic acid strand or the second nucleic acid strand independently have a length of 16 to 35 nucleotides. The 3′ terminus of the two oligonucleotide strands may have an overhang of 0 to 6 nucleotides in length. The small activating nucleic acid molecule for the HMBS gene can be used to up-regulate mRNA and protein expressions of the HMBS gene in a cell and promote enzymatic activity thereof

The invention relates to a MutS protein mutant capable of being combined with mismatched double-stranded nucleic acid with high specificity. The sequence of the MutS protein mutant is as shown in SEQ ID NO: 1. The invention also relates to a fusion protein containing the sequence and an application of the fusion protein in DNA synthesis error correction. According to the invention, a new mutant protein is obtained by carrying out point mutation on the MutS protein, and the protein has higher affinity and specificity on a mismatched double-chain nucleic acid structure in a DNA synthesis process. Therefore, the fidelity rate in the DNA synthesis process can be improved, and after a separation structure is matched, the method can be used for error correction in the high-flux DNA synthesis process, and high-flux and high-fidelity DNA synthesis in an automatic workstation is realized.

Products for detecting a plurality of protein analytes comprise a plurality of proximity probe pairs comprising first and second proximity probes having an antibody or antibody fragment specific for the same protein analyte and a nucleic acid domain, which probes can simultaneously bind to the analyte. Each pair is specific for a different analyte. Each nucleic acid domain comprises an ID sequence and at least a first hybridisation sequence. In each probe pair, ID sequences correspond to a particular analyte, and the probes comprise paired hybridisation sequences. For each probe pair, a splint oligonucleotide comprises hybridisation sequences complementary to each of the paired hybridisation sequences. When probes bind to their protein analyte, the respective paired hybridisation sequences can hybridise to the splint oligonucleotide. At least one pair of hybridisation sequences is shared by at least two pairs of proximity probes. A plurality of sample index oligonucleotides is also included.